Vertex Pharmaceuticals Inc(VRTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:18 PM ET (Korea 10/24 05:18)
Full metrics table
| Index | NDX, S&P 500 | P/E | 30.48 | EPS (ttm) | 17.19 | Insider Own | 0.23% | Shs Outstand | 253.3M | Perf Week | 4.84% |
| Market Cap | 132.80B | Forward P/E | 24.86 | EPS next Y | 12.63% | Insider Trans | -3.94% | Shs Float | 252.9M | Perf Month | 0.3% |
| Enterprise Value | 126.91B | PEG | 2.26 | EPS next Q | 4.8 | Inst Own | 98.58% | Short Float | 1.78% | Perf Quarter | 9.38% |
| Income | 4.41B | P/S | 10.46 | EPS this Y | 1.69% | Inst Trans | 0.11% | Short Ratio | 3.79 | Perf Half Y | 21.76% |
| Sales | 12.70B | P/B | 6.56 | EPS next 5Y | 11.01% | ROA | 17.12% | Short Interest | 4.50M | Perf YTD | 15.57% |
| Book/sh | 79.92 | P/C | 16.89 | EPS past 3/5Y | 6.12% 8.28% | ROE | 23.54% | 52W High | -6.48% ($560.25) | Perf Year | 23.97% |
| Cash/sh | 31.02 | P/FCF | 34.98 | Sales past 3/5Y | 11.34% 14.23% | ROIC | 19.82% | 52W Low | 29.96% ($403.16) | Perf 3Y | 42.5% |
| Dividend Est. | - | EV/EBITDA | 24.22 | EPS Y/Y TTM | 22.53% | Gross Margin | 86.12% | Volatility(W/M) | 2.41% 2.35% | Perf 5Y | 185.49% |
| Dividend TTM | - | EV/Sales | 9.99 | Sales Y/Y TTM | 11.45% | Oper. Margin | 39.54% | ATR (14) | 13.35 | Perf 10Y | 548.75% |
| Dividend Ex-Date | - | Quick Ratio | 2.74 | EPS Q/Q | 8.02% | Profit Margin | 34.69% | RSI (14) | 55.07 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.19 | Sales Q/Q | 11.99% | SMA20 | 2.6% ($510.65) | Beta | 0.29 | Target Price | $575.96 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/2 | SMA50 | 0.23% ($522.73) | Rel Volume | 0.7 | Prev Close | $535.17 |
| Employees | 6400 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | -0.23% 3.2% | SMA200 | 9.75% ($477.38) | Avg Volume(3M) | 1.19M | Price | $523.93 |
| IPO | 1991/7/24 | Option/Short | Yes/Yes | Trades | 23722 | Volume | 832,629 | Change | -2.1% |
🧬 A global leading biotech company specializing in cystic fibrosis therapeutics. Founded in 1989 and headquartered in Boston, Massachusetts, this biotech group has been advancing its cystic fibrosis targeted therapy portfolio alongside the expansion of its new pipeline.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
Next earnings report: November 2
8 days to go.
VRTX makes money exceptionally well
Of every $100 in sales, $39.54 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1.7% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $2,422. Peers typically go for $2,422. Compared with its own 4-year average, it is 12% pricier now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +185.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 98.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It is the largest in the industry
Based on market cap of $133B.
VRTX#1 Vertex Pharmaceuticals Inc $133B PER 30.5 
REGN#2 Regeneron Pharmaceuticals Inc $83B PER 19.9 
MRNA#3 Moderna Inc $80B PER - 
ARGX#4 Argen X SE ADR $55B PER 33.3 
RVMD#5 Revolution Medicines Inc $40B PER - 
FAQ
What kind of company is VRTX?
VRTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRTX?
The market cap of VRTX is approximately $132.8B, ranking 117 within its sector.
What is the P/E ratio of VRTX?
VRTX has a P/E ratio of approximately 30.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VRTX?
VRTX has recorded a 52-week high of $560.25 and a low of $403.16.
